Tirzepatide

Generic Name
Tirzepatide
Brand Names
Mounjaro
Drug Type
Biotech
Chemical Formula
-
CAS Number
2023788-19-2
Unique Ingredient Identifier
OYN3CCI6QE
Background

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety. Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the FDA on May 13, 2022, for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. On September 15, 2022, tirzepatide was also approved by the European Commission.

Indication

Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.

This drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News
morningstar.com
·

Amgen's stock falls as analyst warns that hype around obesity drug is baked in

Truist analyst Srikripa Devarakonda downgrades Amgen stock to hold, citing competition in obesity drug market. She raises price target to $333, but sees limited upside. Amgen's MariTide faces rivals like Novo Nordisk and Eli Lilly. Phase 2 data expected in late 2024.
pharmaphorum.com
·

FDA rethinking block on compounding of Lilly's obesity drug

The FDA agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide, allowing trade to continue while it reviews drug shortages. This follows a lawsuit by the Outsourcing Facilities Association, which claims the FDA's decision to restrict tirzepatide was 'reckless and arbitrary,' potentially leaving patients without treatment.
medwatch.com
·

16 new obesity drugs could be launched by 2029, analysis predicts

Danish Novo Nordisk and American Eli Lilly currently dominate the obesity treatment market with GLP-1 drugs. By 2029, 16 new obesity drugs could be launched, contributing USD 70bn to the GLP-1 market by 2031. The entire GLP-1 market is expected to reach USD 200bn by 2031, with 68% from obesity treatment. Despite new entrants, Novo Nordisk and Eli Lilly are expected to retain two-thirds of the market due to first-mover advantages and innovation.
longportapp.com
·

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want ...

BioAge Labs, a biopharmaceutical company, recently completed its IPO, raising $238.3 million. Its weight loss candidate, azelaprag, aims to help patients lose weight while retaining muscle mass, differentiating it from existing GLP-1 agonists like Ozempic and Mounjaro. While BioAge Labs faces competition from companies like Abbott Laboratories and Altimmune, it remains a high-risk, high-reward opportunity due to its clinical-stage status and potential FDA approval delays.
theglobeandmail.com
·

Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever

Investing $500 in Eli Lilly (NYSE: LLY) and Chipotle Mexican Grill (NYSE: CMG) can yield significant returns. Eli Lilly's revenue surged 36% to $11.3B, driven by GLP-1 drugs and cancer treatments, while Chipotle's revenue rose 18% to $3B, with a 19.7% operating margin. Both stocks offer potential for long-term growth.
discovermagazine.com
·

Off-Brand Ozempic, Zepbound and Other Products Carry Undisclosed Risks

Brand-name injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, despite their high cost (about $800-$1,000 per month) and limited insurance coverage for weight loss, have become billion-dollar sellers due to their effectiveness in weight loss, blood sugar control, and heart disease risk reduction. The FDA resolved a 2022 shortage of the active ingredient in Mounjaro and Zepbound, but patents on semaglutide and tirzepatide extend until 2033 and 2036, respectively, preventing generic versions. Non-brand alternatives, including dietary supplements and compounded drugs, pose risks due to lack of regulation and testing. Compounding pharmacies offer custom versions but are less regulated than commercial manufacturers. Peptide companies exploit loopholes to sell unapproved versions, often without prescriptions, leading to potential health hazards. Eli Lilly and Novo Nordisk have introduced lower-priced alternatives, and future market entrants may further reduce costs.
aol.com
·

Warning: This Skyrocketing Stock Has a Hidden Risk

Eli Lilly's weight loss drugs, Mounjaro and Zepbound, have driven revenue growth, but face pricing pressure from the U.S. government. Despite potential price declines, Lilly's pipeline of new weight loss candidates could mitigate risks.
longportapp.com
·

Good news for obese Americans: FDA considers allowing a combination version of Eli Lilly's weight loss and diabetes treatment drugs

The FDA agreed to reconsider its ban on private drug compounders selling compounded versions of Eli Lilly's weight loss and diabetes treatment drugs, following a lawsuit by the Outsourcing Facilities Association. The compounded versions are cheaper and crucial during shortages of Lilly's official drugs. The FDA's previous decision removed the active ingredient tirzepatide from the shortage list, affecting access for many obese patients. The FDA's reconsideration allows compounding pharmacies to continue providing these drugs, pending a review of ingredient supply.
cnbc.com
·

U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug

The FDA agreed to reconsider its decision to bar drug compounders from selling their own versions of Eli Lilly's weight loss and diabetes drugs, allowing compounding pharmacies to continue providing cheaper alternatives while it reviews a potential shortage of the active ingredient, tirzepatide.
technologyreview.com
·

These are the best ways to measure your body fat

Emma Börgeson and colleagues recommend the SAD measure (sagittal abdominal diameter) as a simpler, affordable alternative to traditional fat measurement methods. SAD, measured by lying on one's back and using a sliding-beam caliper, assesses belly protrusion and is argued to be easier to implement than waist-to-hip measurements.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy